Company news
Neurizon Therapeutics Limited news in 2025
Neurizon Therapeutics Limited's news releases, calls and decks from 2025, newest first.
New Funding Secured for HEALEY ALS Platform Trial
December 22, 2025
Equity Raising Presentation
December 22, 2025
Trading Halt
December 18, 2025
FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
December 11, 2025
Neurizon Completes GMP Tablet Registration Batches
December 3, 2025
Elanco executive appointed as Neurizon's Board Observer
November 26, 2025
Neurizon to present Q1 FY2026 Results
October 30, 2025
Australian Patent Granted for NUZ-001
October 20, 2025
FDA Lifts Clinical Hold on NUZ-001
October 6, 2025
Neurizon Raises $5m via Institutional Placement
September 17, 2025
R&D Tax Incentive Advance & Overseas Finding Approval
September 17, 2025
Appendix 4E and 2025 Annual Report
August 25, 2025
NUZ-001 Shows Long-Term Safety and Efficacy Signals in OLE
August 19, 2025
FDA Review Timeline Extended for NUZ-001 IND Clinical Hold
August 15, 2025
Neurizon Secures Loan Against 2025 R&D Tax Rebate
July 29, 2025
Neurizon Submits Clinical Hold Complete Response to FDA
July 24, 2025
Positive feedback from FDA on strategy to lift clinical hold
July 9, 2025
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
July 2, 2025
Neurizon Enters Global Licensing Agreement with Elanco
July 1, 2025
Neurizon develops liquid formulation of NUZ-001
June 25, 2025
NUZ-001 Shows Significant Blood-Brain Barrier Penetration
June 19, 2025
NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease
June 16, 2025
NUZ-001 Shows Promise in a Model of Huntington's Disease
June 15, 2025
Last Patient Successfully Completes Treatment in OLE Study
May 4, 2025
NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells
April 4, 2025
NUZ-001 Shows Positive Results in Human 3D Brain Model
March 31, 2025
NUZ-001 shows promising respiratory outcome
March 23, 2025
Neurizon Commences Initiatives to Lift Clinical Hold
March 16, 2025
Appendix 4D - Half-year Financial Report - 31 December 2024
February 17, 2025
FDA Guidance on NUZ-001 IND Application
February 16, 2025
US Patent granted for NUZ-001
February 4, 2025
Neurizon updates on NUZ-001 IND Application
January 16, 2025
Decks in 2025
- Investor Presentation (December 2025)
Investor deck · 53 slides · Dec 23, 2025
- Shareholder Meeting (November 2025)
Shareholder meeting · 24 slides · Nov 26, 2025
- Corporate Update (July 2025)
Corporate update · 12 slides · Jul 2, 2025